Press Release Details

Cerus Corporation to Present at the Robert W. Baird Growth Stock Conference

April, 16 2006

CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today that the company will present at Robert W. Baird & Co.'s Growth Stock Conference on Tuesday, May 9, 2006 at 1:55 pm edt. Claes Glassell, President and CEO, and William J. Dawson, Vice President and CFO, will provide an overview of the company.

The conference is being held at the Four Seasons Hotel in Chicago, IL. Interested parties may access a live or archived Internet broadcast of the presentation at The presentation will be archived for 90 days.


Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The Company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vaccine platform with promising disease antigens. These products are designed to stimulate innate and adaptive immune pathways, generating highly specific and highly potent anti-tumor responses. The Company's KBMA vaccine technology has potential broad applications against multiple pathogens. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The Company's strategy is to leverage the broad potential of its technologies and products both on its own and through alliances. Cerus' collaborators include MedImmune and investigators at The Johns Hopkins University for cancer immunotherapy, and BioOne for the INTERCEPT Blood System.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600